AstraZeneca Revenue and Competitors
Estimated Revenue & Valuation
- AstraZeneca's estimated annual revenue is currently $32.8B per year.
- AstraZeneca's estimated revenue per employee is $393,294
- AstraZeneca's current valuation is $182.4B. (January 2022)
Employee Data
- AstraZeneca has 83449 Employees.
- AstraZeneca grew their employee count by 7% last year.
AstraZeneca's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Product Owner | Reveal Email/Phone |
2 | Senior Analyst - Associate Solution Owner | Reveal Email/Phone |
3 | Product Owner/Project Manager | Reveal Email/Phone |
4 | Director, Global Clinical Solutions (Product Owner, System Owner) | Reveal Email/Phone |
5 | Business Process Owner - Logistics | Reveal Email/Phone |
6 | Director/Product Owner | Reveal Email/Phone |
7 | Solution Owner | Reveal Email/Phone |
8 | Service Owner | Reveal Email/Phone |
9 | Omnichannel Solution Owner | Reveal Email/Phone |
10 | Product Owner, Imaging AI | Reveal Email/Phone |
AstraZeneca Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $58.9M | 265 | 10% | N/A | N/A |
#2 | $21.1M | 105 | 5% | N/A | N/A |
#3 | $113.4M | 475 | 2% | N/A | N/A |
#4 | $20.9M | 89 | 3% | N/A | N/A |
#5 | $37M | 184 | 9% | N/A | N/A |
#6 | $45.4M | 62 | -67% | N/A | N/A |
#7 | $16.1M | N/A | N/A | N/A | |
#8 | $69.7M | 347 | 0% | N/A | N/A |
#9 | $8M | 36 | 9% | N/A | N/A |
#10 | $25.5M | 127 | 28% | N/A | N/A |
What Is AstraZeneca?
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
keywords:N/A
N/A
Total Funding
83449
Number of Employees
$32.8B
Revenue (est)
7%
Employee Growth %
$182.4B
Valuation
N/A
Accelerator
AstraZeneca News
AstraZeneca's monoclonal antibody combination tixagevimab-cilgavimab (Evusheld) reduced the risk of symptomatic COVID-19 infection by 83%...
AstraZeneca's Evusheld offers at least 6 months of COVID protection in high-risk patients, study finds ... AstraZeneca has had its share of vaccine setbacks...
Here's a look at those results and how they will affect treatment and prevention. COVID-19 Protection for the Immunocompromised. AstraZeneca's...
PUBLISHED23 November 2021 23 November 2021 00:01 GMT State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem Sustainable environmental engineering aligned to Company's zero carbon future AstraZeneca will today, in the presence of His Royal Highnes ...
Director/PDMR Shareholding Mon, Nov 15, 2021 17:00 CET 15 November 2021 16:00 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that on 12 November 2021 an award of AstraZeneca American Depositary Shares (ADSs) vested to Dr Aradhana Sari ...